Ozempic, Wegovy, Mounjaro… These new drugs are generating enthusiasm among patients suffering from diabetes and obesity, two indications for which marketing has been authorized. After several decades of failure to effectively treat obesity, the clinical results of so-called “GLP-1 analogues” (glucagon-like peptide-1 hormone) indeed seem very promising.
But this excitement does not stop there. In recent months, data on the supposed virtues of this new class of drugs in other pathologies have multiplied. Observational studies highlight beneficial effects on cardiovascular risk, as well as kidney failure.
Researchers also believe that these drugs would be effective in treating addictions. GLP-1 analogues would in fact regulate other sensations of pleasure than that provided by food. A research article published in the JAMA reported a study showing that patients treated with these drugs had less desire to smoke. On the other hand, “the data are more controversial for alcohol”recognizes Dominique Deplanque, president of the French Society of Pharmacology and Therapeutics.
You have 72.41% of this article left to read. The rest is reserved for subscribers.
Health
